ReviewFrontiers in immunology2026
Immune complex handling in transplantation: central roles for complement factor H, animal models, and translational implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune complexes (ICs) are increasingly recognized as dynamic regulators of graft injury in solid organ transplantation. Beyond their formation, the biological impact of ICs is determined by how they are handled, trafficked, and cleared. Complement plays a central role in this process, functioning not only as an effector system but as a context-dependent regulator of IC fate. Classical pathway activation initiates complement deposition on ICs, while the alternative pathway amplifies these signals, with regulatory proteins constraining excessive activation. Complement factor H (CFH), the principal regulator of the alternative pathway, emerges as a key determinant of IC handling by modulating complement amplification and directing ICs toward non-inflammatory clearance pathways. This review integrates mechanistic insights into IC biology with clinical observations across kidney, heart, and lung transplantation. We highlight species-specific differences in IC clearance, examine how complement-targeted therapies intersect with IC biology, and address ongoing controversies regarding complement as a marker versus driver of injury. Collectively, these concepts position IC handling, not merely for IC formation, but as a central determinant of transplant outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.